Onco Wiki / Biomarcador

Carga viral do ADN-EBV (PCR quantitativa, plasma)

Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.

IDBIO-EBV-DNA
TipoBiomarcador
Alegais
PCR do EBVCarga viral do EBVCarga quantitativa do ADN-EBVAvaliação do risco de doençaВірусне навантаження EBV-DNA (кількісна ПЛР, плазма)
Estadoreviewed 2026-04-26 | pending_clinical_signoff
DoençasDIS-NK-T-NASAL DIS-NPC DIS-PTLD
FontesSRC-NCCN-BCELL-2025

Fatos de biomarcadores

Tipo de biomarcadorviral_load
Medição
MétodoReal-time quantitative PCR for EBV-DNA on cell-free plasma (preferred) or whole blood. Plasma EBV-DNA reflects active viral replication and tumor lysis; whole-blood EBV-DNA includes latent virus in B-cells and is less specific for active disease. Standardized in IU/mL via WHO international standard.
UnidadesUI/ml (ou cópias/ml com conversão específica para o ensaio)
Gama típica
  • 0
  • 100000000
Biomarcadores relacionadosBIO-EBV-STATUS BIO-HIV-STATUS

Notas

Companion to BIO-EBV-STATUS (qualitative tissue EBER-ISH). EBV-DNA is the *quantitative* serum marker used for: - **Extranodal NK/T nasal-type lymphoma**: pre-treatment baseline; monitoring during SMILE / DDGP / asparaginase-based regimens; post-treatment surveillance. Rising EBV-DNA on therapy correlates with poor response; persistent post-treatment positivity predicts relapse. - **PTLD**: EBV-driven PTLD shows EBV-DNA load decrease with rituximab + reduced immunosuppression; trend is response surrogate. - **HIV-associated EBV+ DLBCL / plasmablastic / primary effusion**: contextual; not standardly used for treatment decisions. - **Post-HSCT monitoring**: weekly EBV-DNA used to detect early PTLD risk; preemptive rituximab if doubling. Wired into: ALGO-NK-T-NASAL-1L (notes only — full Monitoring entity with thresholds and frequency to be authored). reviewer_signoffs: 0 # STUB — pending two Clinical Co-Lead approvals

Usado por

Doença

Indicação

Questionários

Sinal de alerta

Fontes